Myotonic Dystrophy type 1 (DM1) is caused by an expansion of CUG repeats in DMPK mRNAs. This mutation affects alternative splicing through misregulation of RNA-binding proteins. Amongst pre-mRNAs that are mis-spliced, several code for proteins involved in calcium homeostasis suggesting that calcium-handling and signaling are perturbed in DM1. Here, we analyzed expression of such proteins in DM1 mouse muscle. We found that the levels of several sarcoplasmic reticulum proteins (SERCA1, sarcolipin and calsequestrin) are altered, likely contributing to an imbalance in calcium homeostasis. We also observed that calcineurin (CnA) signaling is hyperactivated in DM1 muscle. Indeed, CnA expression and phosphatase activity are both markedly increased in DM1 muscle. Coherent with this, we found that activators of the CnA pathway (MLP, FHL1) are also elevated. Consequently, NFATc1 expression is increased in DM1 muscle and becomes relocalized to myonuclei, together with an up-regulation of its transcriptional targets (RCAN1.4 and myoglobin). Accordingly, DM1 mouse muscles display an increase in oxidative metabolism and fiber hypertrophy. To determine the functional consequences of this CnA hyperactivation, we administered cyclosporine A, an inhibitor of CnA, to DM1 mice. Muscles of treated DM1 mice showed an increase in CUGBP1 levels, and an exacerbation of key alternative splicing events associated with DM1. Finally, inhibition of CnA in cultured human DM1 myoblasts also resulted in a splicing exacerbation of the insulin receptor. Together, these findings show for the first time that calcium-CnA signaling is hyperactivated in DM1 muscle and that such hyperactivation represents a beneficial compensatory adaptation to the disease.
Introduction
Myotonic Dystrophy type 1 (DM1) is a multisystemic disorder affecting skeletal muscle and other organs including the brain, heart, eyes and endocrine system. The disease is caused by an autosomal dominant mutation that corresponds to an expansion of CUG repeats (CUG exp ) located in the 3 0 untranslated region (3 0 UTR) of dystrophia myotonica protein kinase (DMPK) mRNAs. CUG exp mutant mRNAs aggregate in the nucleus, sequestering and misregulating RNA-binding proteins (RBP) normally destined to regulate other cellular processes. Amongst RBP that are misregulated in DM1, CUGBP Elav-like family member 1 (CUGBP1, also known as CELF1) (1, 2) and muscleblind-like protein 1 (MBNL1) (3), have received considerable attention. In this context, our recent work has also established Staufen1 as another RNA-binding protein that is misregulated in skeletal muscle from DM1 patients and mouse models (4) (5) (6) (7) (8) . Since MBNL1, CUGBP1 and Staufen1 are splicing regulators, their imbalance alters normal alternative splicing patterns in DM1. Indeed, aberrant splicing of the insulin receptor (IR), chloride channel (ClC-1) and cardiac voltage-gated sodium channel (SCN5A) pre-mRNAs can account for symptoms such as insulin resistance, myotonia and cardiac conduction defects, respectively (9) (10) (11) . Accordingly, DM1 is seen as a spliceopathy which, to some extent, explains the multisystemic and complex nature of the phenotype (12) (13) (14) . In addition to alternative splicing, these RBP assume other functions that also impact DM1, including micro-RNA biogenesis (15) , modulation of translation and RNA stability (16, 17) and the stress response (6, 18) . However, several aspects of the disease and key pathological features are still poorly understood. In skeletal muscle, intracellular calcium concentration (or [Ca 2þ ] i ) plays an important role in multiple events impacting muscle physiology and phenotype. The sarcoplasmic reticulum (SR) actively participates in the regulation of calcium homeostasis. During myofibrillar contraction, T-tubule membrane depolarization activates voltage-dependent dihydropyridine receptors (DHPR, also known as Ca V 1.1) which interact with, and trigger the opening of ryanodine receptors (RyR) thereby releasing calcium from the SR (19) . Following contraction, cytosolic calcium is pumped back into the lumen of the SR by the action of the sarco/endoplasmic reticulum calcium-ATPase (SERCA) pumps whose activity is regulated by the small SR membrane peptides phospholamban (PLB) and sarcolipin (SLN) (20, 21) . Calcium signaling is essential in muscle because it affects multiple cellular processes including the regulation of muscle adaptation and plasticity via the control of gene and protein expression. Specifically, variations in [Ca 2þ ] i are known to activate calmodulin (CaM) which in turn promotes activation of calcium/CaM-dependent kinases (CaMK) and phosphatases (22) . Over the years, there has been a great deal of attention focused on the phosphatase calcineurin (Cn) because of its pivotal role in muscle adaptation and disease (22) (23) (24) (25) . Cn consists of a heterodimer formed by the association of the calcineurin A (CnA) catalytic subunit and the CnB regulatory subunit. CnA stimulates the activity of nuclear factor of activated T-cell (NFAT) transcription factors through dephosphorylation. Activated, dephosphorylated NFAT translocates to nuclei where it binds to promoter regions of target genes thereby up-regulating their expression. In muscle, binding of NFAT to target promoters, enables the expression of the slow, oxidative myogenic program (26) while also participating in the control of muscle fiber size (23, 24) .
Within pre-mRNAs that are aberrantly spliced in DM1, several code for proteins involved in calcium homeostasis. Indeed, aberrant alternative splicing of DHPR, RyR1 and SERCA1 are observed in DM1 muscle. While DHPR aberrant splicing affects channel conductance and voltage sensitivity (27) , RyR1 and SERCA1 mis-splicing affects excitation-contraction (EC) coupling (28) and pump activity (29) , respectively. Furthermore, Bridging Integrator 1 (BIN1), which colocalizes with DHPR and regulates T-tubule formation, also exhibits mis-splicing in DM1 resulting in the expression of an inactive protein (30) . Collectively, these findings suggest that calcium homeostasis is altered in DM1 muscle, and influences disease mechanisms and progression.
Over the years, much of the attention in DM1 has focused on the misregulation of RBP and the impact on muscle phenotype.
In contrast, there is little information on the state of signaling pathways that may also be affected thereby contributing to disease pathogenesis. Given the changes in alternative splicing of calcium-handling proteins in DM1, which likely affect calcium dynamics, it seems reasonable to postulate that DM1 is accompanied by important changes in calcium-CnA signaling. We have thus examined the level of expression of several calciumhandling and signaling proteins in DM1 skeletal muscle and determined their impact on muscle phenotype. Our results show the CnA signaling pathway is hyperactivated in DM1 skeletal muscle and that it represents a beneficial compensatory adaptation to this disease.
Results
Levels of calcium-handling and signaling proteins are altered in DM1 mouse muscle
To assess the level of calcium-handling and signaling proteins in DM1 muscle, we performed western blots using protein extracts obtained from extensor digitorum longus (EDL) muscles from control and DM1 mice. For this, we used the wellestablished HSA-LR (human skeletal actin-long repeat) DM1 mouse model which carries a non-disease transgene with 250 CTG repeats in the 3 0 UTR (31).
First, we analyzed expression levels of proteins involved in calcium homeostasis. SERCA is an ion channel ATPase pumping calcium into the lumen of the SR. Two isoforms are expressed in skeletal muscle, the fast isoform SERCA1 and the slow isoform SERCA2. While no difference was observed in SERCA2 levels, a 32% decrease in SERCA1 was seen in DM1 mouse muscle compared to controls (P ¼ 0.05) (Fig. 1A and B) . SERCA activity is regulated by two homologous SR membrane proteins, PLB and SLN. Both bind to, and inhibit SERCA activity (20, 21) . Our data show that while the expression of PLB remains unchanged, SLN steady-state levels are variable, but show a trend towards an increase of $4-fold in DM1 mouse muscles compared to wild-type (P ¼ 0.1) (Fig. 1A and C) . Given the low signal obtained by western blots, we also measured SLN transcript levels by quantitative RT-PCR, and observed a $2-fold increase (P ¼ 0.02) in SLN mRNAs in DM1 EDL mouse muscles compared to controls (Supplementary Material, Fig. S1 ). In addition, we observed a $36% decrease in calsequestrin (CSQ), an SR calcium-buffering protein, in DM1 mice (P ¼ 0.05) (Fig. 1A and D) .
We also analyzed expression of proteins involved in calcium signaling. For this, we measured the level of the phosphatase CnA. We observed a $2-fold increase in CnA levels in DM1 mouse muscles (P ¼ 0.0007) ( Fig. 2A and B) . In these samples, this CnA increase was accompanied by a $2.5-fold increase in CnA phosphatase activity (P ¼ 0.0007) (Fig. 2C) . We further confirmed this increase in CnA in a different set of samples (P ¼ 0.002), and analyzed the level of regulators of CnA. In DM1 mouse muscle, the CnA increase was not accompanied by a change in the expression of CaM (P > 0.05) ( Fig. 2D and E) . Levels of Calsarcin2 (32, 33) and Regulator of Calcineurin 1 (RCAN1) isoform 1 (RCAN1.1), two binding partners and inhibitors of CnA, remained unchanged between control and DM1 mouse muscle (P > 0.05) (Fig. 2D and F) . These findings show that inhibitors of the CnA pathway appear unaltered in DM1 skeletal muscle.
We then assessed the levels of activators of the CnA signaling pathway by examining muscle LIM protein (MLP) which interacts with CnA to increase its activity (34) . We observed a marked $5.5-fold increase in MLP in DM1 muscle (P ¼ 0.0001) (Fig. 2D and G) . The four and a half LIM domain protein 1 (FHL1) binds directly to NFATc1 and enhances its transcriptional activity (35, 36) . Similar to what we observed with MLP, both FHL1-A and FHL1-B isoforms are up-regulated in DM1 mouse muscle (P ¼ 0.05 and 0.02, respectively) ( Fig. 2D and G) .
It is well-established that activated CnA dephosphorylates the transcription factor NFAT leading to its nuclear translocation (37) . To evaluate NFATc1 localization, we performed immunofluorescence experiments using anti-NFATc1 antibodies on cryostat cross-sections obtained from control and DM1 EDL mouse muscles. First, we observed a more pronounced staining of NFATc1 in myonuclei from DM1 mice (Fig. 3A and Supplementary Material, Fig. S2 ). Second, this increased nuclear localization of NFATc1 was accompanied by an increase in total NFATc1 steady-state levels. Indeed, both $110 (P ¼ 0.03) and $140 (P ¼ 0.01) kDa NFATc1 isoforms were up-regulated in DM1 mouse muscles, with the longer isoform displaying a greater increase ( Fig. 3B and C) .
Finally, gene expression of both RCAN1 isoform 4 (RCAN1.4) and myoglobin are known to be activated by CnA through NFAT, and can therefore be used as reporters of CnA signaling activation (26, 38, 39) . We found that levels of both RCAN1.4 and myoglobin are strongly up-regulated by more than $20-and DM1 EDL muscles. a-Tubulin was used as a loading control. ß-Actin2 was used as loading control for Myoglobin. N ¼ 4 (11-12 week-old females). T-tests were used, and asterisks indicate significance (*P 0.05, **P 0.01 and ***P 0.001).
$8-fold (P ¼ 1 Â 10 À5 and 0.01, respectively) in DM1 mouse muscle ( Fig. 2D and H) . Altogether, these results show that the CnA signaling pathway is hyperactivated in DM1 mouse muscle.
Muscles of DM1 mice display a switch to an oxidative phenotype Activation of the CnA signaling pathway is known to promote the slow, oxidative program in muscle (40) . To determine whether changes in calcium signaling in DM1 mice are accompanied by changes in metabolic properties of DM1 muscles, we thus examined several metabolic characteristics. We first noticed that EDL muscles dissected from DM1 mice appeared redder in color compared to their wild-type counterparts (Fig. 4A ). This red color is a characteristic of higher concentration of myoglobin, which correlates nicely with the higher level of myoglobin observed by western blot in DM1 mouse muscle (see above and Fig. 2D and H) . Importantly, this increased reddish color was also observed upon dissection of gastrocnemius and tibialis anterior muscles from DM1 mice (Supplementary Material, Fig. S3 ). We then characterized oxidative phosphorylation (OXPHOS) content by western blots using antibodies specific for complex I (CI, NADH:Ubiquinone Oxidoreductase Subunit B8, NDUFB8), CII (Succinate Dehydrogenase Complex Iron Sulfur Subunit B, SDHB), CIII (Ubiquinol-Cytochrome C Reductase Core Protein II, UQCRC2), CIV (Mitochondrial Cytochrome C Oxidase I, COX1 also known as MTCO1) and CV (ATP synthase subunit alpha, ATP5A). While large differences were not observed in complex I, II, III and V levels, we noted a marked increase ($7-fold, P ¼ 0.0001) in complex IV COX1 expression ( Fig. 4B and C) , indicating that DM1 mouse muscles display a more oxidative phenotype.
This analysis was complemented with the characterization of fiber type composition of DM1 mouse skeletal muscle. To this end, we performed immunofluorescence experiments on serial cryostat cross-sections using anti-myosin heavy chain (MyHC) antibodies specific for different MyHC isoforms. Serial crosssections were performed at the same level, same depth, for all muscles, and the entire EDL muscle surface was used for fiber typing to ensure a reliable and unbiased quantification caused by regional differences. MyHC immunofluorescence staining of cross-sections taken from the same muscle for control and DM1 mice are displayed in Figure 4D . As expected in fast-twitch EDL muscles from wild-type mice, we observed a very small percentage (<2%) of slow-twitch MyHC type I-positive fibers. This was also seen in DM1 mouse muscle. Moreover, we did not observe any significant difference in the percentage of the three fasttwitch MyHC isoforms, i.e. type IIa, IIx and IIb, in DM1 mouse muscle compared to controls (P > 0.05) ( Fig. 4D and E) .
Activation of CnA signaling is also known to be linked to muscle fiber hypertrophy (23, 24, (41) (42) (43) (44) . To determine whether the hyperactivation of CnA in DM1 mouse muscle is paralleled by an increase in fiber size, we performed H&E staining on cryostat cross-sections. We observed an increase in fiber size variability in DM1 mouse muscle, with larger fibers being clearly visible in specific areas (Fig. 4F ). Due to the non-homogenous distribution and variability in the size of muscle fibers, it was also necessary to analyze cross-sectional areas (CSA) of the entire muscle surface. To this end, we used laminin staining to delineate individual fibers (Fig. 4D) . Our results showed an increase in the mean fiber size from 939 653 to 1188 6152 lm 2 (P ¼ 0.08, mean 6SEM) in DM1 mice ( Fig. 4D and F) , without a T-tests were used, and asterisks indicate significance (*P 0.05 and **P 0.01).
parallel increase in the total number of fibers (693 665 and 688 627 for control and DM1 mice, respectively; P > 0.05). This was accompanied by an increase in fiber size variability as characterized by an increase in the variance coefficient (VC) from 559 641 to 668 620 (P ¼ 0.03, mean 6SEM) ( Fig. 4D and F) . We also analyzed the distribution of muscle fibers based on their size. As shown in Figure 4G , we observed a global increase in the number of large muscle fibers, and a reciprocal decrease in smaller ones, in DM1 mice. By evaluating the results from fiber typing and CSA, we noticed that this increase in fiber diameter affects mainly IIx-and IIb-positive fibers (Fig. 4D , F and G). Together, these data show that activation of CnA signaling in DM1 mouse muscle is accompanied by muscle fiber hypertrophy and an increase in oxidative metabolism but without a fiber MyHC-type shift, thereby implying a clear dissociation between the contractile and metabolic properties of DM1 mouse muscle fibers.
CnA inhibition reverts the increased oxidative metabolism in DM1 mouse muscle
Cyclosporine A (CsA) is a potent pharmacological inhibitor of CnA that is clinically used for several conditions. In cells, CsA binds to, and inhibits CnA activity, thereby preventing the downstream activation and nuclear translocation of NFAT (45) . To decipher the importance of the CnA pathway in DM1 muscle cells, we treated 12 week-old DM1 mice (HSA-LR) with CsA. Subcutaneous injections were performed twice daily at a dose of 25 mg/kg/day under aseptic conditions (41, 46) . Four weeks later, muscles were dissected from control, saline-treated DM1 mice and CsA-treated DM1 mice.
During the second week of treatment, we noticed a behavioral change in CsA-treated DM1 mice. Mice were hunched, lethargic and showed signs of dehydration. Two mice in the cohort of 10 died by the end of the second week of CsA-treatment. From that time point, all mice were injected daily with saline and provided with free access to hydration gel and wet food chow to keep animals hydrated. Over the years, we have performed several CsA treatments on control and dystrophic mice (41, 46) , but such effects were never observed on CsA-treated animals, suggesting that inhibiting CnA signaling pathway has a major negative physiological impact on DM1 mice.
To assess the effect of CsA injections on oxidative metabolism in DM1 mice, we performed western blots on EDL protein extracts using anti-OXPHOS antibodies ( Fig. 5A and B) . First, while differences in complex I, II, II and V were not observed, complex IV COX1 expression was increased by more than $5-fold in saline-injected DM1 mice compared to wild-type (P ¼ 0.005) ( Fig. 5A and B) . This corroborates nicely with the increase in complex IV COX1 in a second independent set of DM1 mice (compare Figs 4B and 5A). Second, CsA treatment in DM1 mice induced a marked decrease in COX1 expression to control levels ( Fig. 5A and B ). This demonstrates both the efficiency of the CsA treatment and the role of CnA signaling in promoting oxidative metabolism in DM1 mouse muscles.
We then performed a histological analysis of mouse muscles on cryostat cross-sections to assess the effect of CnA inhibition on characteristic features of DM1. One of the hallmarks of DM1 is the increase in central nucleation (31) . Cryostat cross-sections performed at the same level, same depth, of the muscle were stained with H&E. Three random pictures per EDL muscle were used, and nuclei were considered central if they were not in contact with the periphery of the muscle fiber. Our analysis showed the typical increase in central nucleation in salineinjected DM1 mice compared to controls (P ¼ 5 Â 10 À6 ) ( Fig. 5C and D). However, CsA treatment did not affect the percentage of central nucleation in DM1 mice (P > 0.05) ( Fig. 5C and D) . Next, we measured CSA on laminin stained cross-sections ( Fig. 5E and F). We observed a decrease in the percentage of small fibers and a reciprocal increase in the percentage of large fibers in saline-injected DM1 muscles compared to wild-type, thereby confirming the fiber hypertrophy seen in DM1 mice in a second independent set of animals (compare Figs 4G and 5E). However, CsA treatment of DM1 mice did not change the distribution of fiber CSA compared to saline-injected DM1 mice (P > 0.05). We also performed fiber typing on serial cryostat cross-sections using MyHC isoform-specific antibodies. MyHC immunofluorescence staining of cross-sections taken from the same muscle for control and DM1 mice are displayed in Figure 5F . Our results show that the CsA treatment had no major impact on MyHC fiber type distribution in DM1 mouse muscle except for a modest increase in the number of IIx fibers (P ¼ 0.02) ( Fig. 5F and G).
CnA inhibition increases CUGBP1 levels and exacerbates the DM1 spliceopathy
In DM1, MBNL1 is sequestered within nuclei by mutant CUG exp mRNAs, thereby reducing its functional availability in cells (3).
In turn, such misregulation of MBNL1 affects alternative splicing of pre-mRNA targets. We therefore first assessed the extent of aggregation of toxic CUG exp mRNAs by fluorescence in situ hybridization (FISH) on muscle cross-sections using a Cy3-(CAG)10
probe. Microscopic analysis revealed the formation of classic CUG exp -containing nuclear RNA foci in saline-injected DM1 mouse muscle. However, no difference in RNA foci formation was observed between saline-and CsA-treated animals (Fig. 6A) . We next determined MBNL1 localization by immunofluorescence using anti-MBNL1 antibodies. Similar to what we saw with nuclear foci, we did not observe any difference in MBNL1 sequestration between saline-and CsA-treated DM1 mice (Fig. 6B) .
To complement these experiments, we also measured levels of Staufen1, CUGBP1 and MBNL1 by western blots. Total proteins were extracted from EDL and plantaris muscles from control, saline-or CsA-treated DM1 mice. In agreement with our original findings (4), we observed an increase in Staufen1 levels in EDL muscles from DM1 mice compared to controls ($1.8-fold; P ¼ 0.002) (Supplementary Material, Fig. S4 ). While the increase of CUGBP1 is well-established in human DM1 skeletal muscle and heart tissue samples (9, 47) , in DM1 myoblasts in culture (48) and in some DM1 mouse models (49-51), some variability seems to exist in HSA-LR transgenic mice (52, 53) , likely due to age and gender differences as well as to the specific muscle examined. Here, we observed no difference in MBNL1 (P > 0.05), but detected a modest decrease in CUGBP1 levels in EDL muscles from HSA-LR mice (P ¼ 0.03) (Supplementary Material, Fig. S4 ). Furthermore, following 4 weeks of CsA treatment, no difference was seen in the level of Staufen1 (P > 0.05) (Fig. 6C and D) . However, we observed a pronounced $2.7-fold increase in the expression of CUGBP1 in both EDL and plantaris muscles from CsA-treated DM1 mice (P ¼ 0.002), and a $1.5-fold increase of MBNL1 in EDL muscle (P ¼ 0.002) (Fig. 6C and D) .
Since DM1 is a disease caused by a misregulation of premRNA splicing, we examined the splicing patterns of key premRNAs relevant for DM1 including SERCA1, DHPR, TNNT3, RyR1 and CAPZB. SERCA1 has two major isoforms resulting from alternative splicing of exon 22: an adult SERCA1a (þE22) and neonatal SERCA1b (ÀE22). Skipping of exon 22, which contains a stop codon, leads to a longer C-terminus end in SERCA1b protein. Coherent with previous reports (29,52), we observed an increased exclusion of exon 22 in saline-injected DM1 mouse muscle from 0% exclusion in wild-type to $58 and 50% in both EDL and plantaris muscles, respectively (Fig. 7A-D) , showing that DM1 mice express the neonatal SERCA1b isoform. CsA-treatment of DM1 mice caused a further increase in exon 22 exclusion to $70% SERCA1b in EDL (P ¼ 0.03) and to $63% in plantaris (P ¼ 0.02) muscles (Fig. 7A-D) .
DHPR (Ca V 1.1) exon 29 aberrant splicing is associated with muscle weakness in DM1 (27) . Indeed, exclusion of exon 29 affects channel conductance and voltage sensitivity, thereby impacting EC coupling. In agreement with previous studies (27), we observed an increase in exon 29 skipping from 0 to $15 and $6% in plantaris and EDL muscles, respectively (Fig. 7A-D) . CsAtreatment of DM1 mice further promoted this increased skipping of exon 29 to $22 and $17% in plantaris and EDL muscles, respectively (P ¼ 0.01 and 0.0007, respectively) ( Fig. 7A-D) .
Troponin T type 3 (TNNT3) contains several alternatively spliced exons including a fetal exon F. Inclusion of exon F affects the biological function of TNNT3 protein, in particular its calcium-regulated ATPase activity (54) . As previously shown (55) , exon F inclusion is increased in DM1 compared to controls, together with different combinations of alternatively spliced exons 4-8, which produces multiple mRNAs containing exon F (Fig. 7A and C) . While several bands including exon F are produced in saline-injected DM1 mice, we observed that CsA increased the proportion of one specific exon F-containing transcript from 7% in saline-injected DM1 to 18 and 14% in plantaris and EDL muscles, respectively (P ¼ 0.02 and 0.01, respectively) (arrow head in Fig. 7A, C and quantifications Fig. 7B, D) . Altogether, these findings indicate that CsA treatment of DM1 mice increases aberrant alternative splicing of SERCA1, DHPR and TNNT3 in muscle thereby indicating that CnA inhibition exacerbates the spliceopathy seen in DM1 mice.
Alternative splicing of exon 70 produces two isoforms of RyR1 (29) . In DM1, exon 70 exclusion is increased which may perturb EC-coupling (28) . As expected (29), we observed an increase in RyR1 exon 70 exclusion from 44% in wild-type mice to 68% in saline-injected DM1 plantaris ( Fig. 7A and B) and from 29 to 71% in EDL (Fig. 7C and D) . This shows that DM1 mice express the altered form of RyR. However, CsA treatment had no effect on RyR1 alternative splicing (P > 0.05). Capping actin protein of muscle Z-line beta subunit (CAPZB) exon 8 alternative splicing is known to be regulated by CUGBP1 expression (27, 56) . Given the increase seen in CUGBP1 levels in DM1 mouse muscles following CsA treatment (see Fig. 6C-F) , we also examined the splicing pattern of CAPZB in both plantaris and EDL muscles following CsA treatment. As expected (52) , no major changes (P > 0.05) in the regulation of CAPZB splicing in DM1 mouse T-tests were used, and asterisks indicate significance (*P 0.05, **P 0.01 and ***P 0.001). muscles was observed. As seen also with RyR1 pre-mRNAs, CsA treatment failed to alter this splicing profile (Fig. 7A-D) .
CnA inhibition increases IR aberrant alternative splicing in human DM1 myoblasts
To determine whether CnA also modulates alternative splicing in human DM1 cells, we treated DM1 patient-derived cells in culture with CsA and analyzed the alternative splicing pattern of the IR pre-mRNA. Human DM1 primary fibroblasts were first converted into myoblasts by infection with a MyoD-lentivirus as previously described (4, 6) . Three to five days following infection, MyoD-converted DM1 myoblasts were treated with increasing concentrations of CsA to inhibit CnA. Forty-eight hours later, alternative splicing profiles were analyzed by RT-PCR. A hallmark of the DM1 pathology is insulin resistance caused by missplicing of the IR. In DM1 cells, exon 11 of human IR pre-mRNAs is preferentially skipped resulting in an IR with lower signaling capacity (9) . Our results show that inhibition of CnA by CsA induced a dose-dependent decrease in exon 11 inclusion from $47 to $33% at a dose of 800 nM of CsA (P ¼ 0.03) (Fig. 8A) . These results show that CsA treatment of DM1 muscle cells favor further skipping of exon 11 and expression of the IR isoform associated with insulin resistance. These data are therefore coherent with the data obtained in vivo with CsA treatment of DM1 mice (Fig. 7A-D) showing that inhibition of CnA exacerbates the DM1 phenotype.
Discussion
In this study, we performed a detailed analysis of proteins involved in calcium homeostasis and signaling in muscles from an adult-onset DM1 mouse model. Our results show that expression of several SR calcium-handling proteins (SERCA1, SLN and CSQ) is altered in skeletal muscle of DM1 mice. In addition, we provide evidence that CnA signaling is hyperactivated in DM1 mouse muscle with specific components being clearly affected. Indeed, we observed a marked increase in CnA expression and phosphatase activity, as well as in activators (MLP, FHL1) of this pathway. Consequently, NFATc1 levels is also increased in DM1 mouse muscle, and relocalizes to myonuclei, while expression of known targets of this pathway (RCAN1.4 and myoglobin) is also up-regulated. Therefore, these findings show for the first time that CnA signaling is hyperactivated in DM1 mouse muscle. Accordingly, skeletal muscles from DM1 mice display an increase in oxidative metabolism and muscle fiber hypertrophy. In addition to reporting this hyperactivation of CnA signaling, we also show in the present work that pharmacological inhibition of CnA signaling reverts oxidative metabolism to control levels, but caused an increased in CUGBP1 levels as well as further mis-splicing of some relevant pre-mRNAs thereby resulting in an exacerbation of the DM1 spliceopathic phenotype. Coherent with these results, we observed that CnA inhibition in cultured human DM1 muscle cells also exacerbates alternative splicing of IR pre-mRNAs. Altogether, these findings indicate that the hyperactivation of CnA signaling in DM1 muscle represents a beneficial compensatory adaptation to the disease (see model in Fig. 9 ).
In DM1, several pre-mRNAs that are known to be aberrantly spliced code for proteins involved in calcium homeostasis such as the SR proteins SERCA1 and RyR1 (29) , and the T-tubule-associated proteins DHPR/Ca V 1.1 (27) and BIN1 (30) . Alternative splicing of these pre-mRNAs in adult DM1 favors expression of embryonic isoforms of these proteins, and each can impact their normal function in adult DM1. Therefore, it has been hypothesized that aberrant alternative splicing events in DM1 alter calcium homeostasis. In addition to alternative splicing, microarray studies using biopsies from DM1 patients (57, 58) and mouse models (59, 60) revealed variations in the transcript levels of calcium-handling proteins. However, information concerning their respective protein expression in adult DM1 remains fragmentary. Here, we show that the steady-state level of these proteins is affected in the widely accepted HSA-LR mouse model of DM1. Amongst the proteins we examined, SERCA1 is downregulated and SLN is up-regulated in DM1 muscle. In this context, it is interesting to note that, as we have also seen here with EDL muscles, SLN mRNAs were previously found to be elevated in a microarray performed with quadriceps (vastus) muscles from HSA-LR mice (59) . SLN, is a small membrane peptide known to inhibit SERCA1 activity in skeletal muscle (61) . Therefore its elevated levels likely inhibit SERCA1 activity in DM1 muscle. As part of our analysis, we also found a significant decrease in the level of the SR calcium-buffering protein CSQ in DM1 muscle, which likely reduces the capacity of DM1 muscle fibers to store calcium into the SR lumen.
Our observation that SERCA1, SLN and CSQ levels are misregulated in DM1 suggests that the SR has a decreased capacity for pumping calcium back into it for storage and subsequent cycles of release. Based on these changes, one can easily predict that the inhibition of calcium uptake by the SR coupled to a ] i levels in DM1 muscle fibers (62, 63) , and more recent work confirmed this increase in [Ca 2þ ] i in primary DM1 myotubes in culture (64) . Interestingly, human subjects treated with the cholesterollowering drug Triparanol, a drug known to increase [Ca 2þ ] i , develop symptoms usually associated with DM1, including myotonia, cataracts and baldness (65) , supporting the idea that calcium misregulation participates in the etiology of DM1. In future work, it will be important to determine whether [Ca 2þ ]i is also increased in skeletal muscles from available DM1 mouse models including HSA-LR mice. Taken together with the reported splicing changes, our findings suggest that calcium homeostasis is affected in DM1 muscle thereby impacting disease mechanisms and progression.
Rises in [Ca 2þ ] i are known to trigger various calciumdependent signaling pathways. In particular, calcium-bound CaM triggers activation of CnA signaling (22, 43, 66) . Given the changes observed in calcium-handling proteins in DM1 mouse muscle, we hypothesized that the resulting imbalance in calcium homeostasis would activate CnA signaling. In the present study, we show that the calcium-CnA pathway is indeed hyperactivated in DM1 mice together with marked increases in known activators as well as downstream targets of this pathway.
CnA is an important regulator of muscle plasticity. In particular, CnA activation is known to promote a more oxidative muscle fiber phenotype (26) . Coherent with this, we show here that DM1 mouse muscles display a more oxidative metabolism. Importantly, this increase in oxidative metabolism was reverted by pharmacological inhibition of CnA with CsA. Activation of the CnA pathway is also known to promote the transition of muscle fibers towards a slower phenotype. In our experiments, however, we did not observe any major changes in fiber MyHCtype composition in DM1 mouse muscle, indicating a clear dissociation between oxidative metabolism and fiber type in DM1.
In addition to its key role in controlling the slower oxidative phenotype, CnA activation is known to also regulate muscle fiber size of all MyHC types, in particular during the hypertrophic response induced by functional muscle overload (23, 24) . In agreement with this, we observed a marked increase in fiber size variability in DM1 mouse muscle with a robust increase in fiber hypertrophy affecting more specifically type IIx and IIb fibers. It is important to note, however, that fiber hypertrophy in these DM1 mouse muscle was limited to IIx and IIb fibers likely because the HSA promoter drives expression of the pathological CUG exp transgene predominantly in fast-twitch fibers (67, 68) .
To decipher the importance of the hyperactivation of CnA in DM1, we treated HSA-LR mice with CsA, a pharmacological inhibitor of CnA, for 4 weeks. Our results show that CsAtreatment of DM1 mice increased markedly CUGBP1 levels in both plantaris and EDL muscles. These changes in the expression of CUGBP1 were accompanied by increased aberrant alternative splicing. In our work, we chose to analyze five wellcharacterized alternative splicing events in DM1 mouse muscles, namely, SERCA1, DHPR, TNNT3, RyR1 and CAPZB. Inhibition of CnA further increased exon 22 exclusion in SERCA1, exon 29 exclusion in DHPR and promoted the expression of one specific exon F-containing isoform in TNNT3. All of these events would aggravate the DM1 phenotype. To complement these experiments, we analyzed the effect of CnA inhibition in cultured human DM1 myoblasts and observed a similar negative impact of CsA on a key alternative splicing event relevant for DM1, i.e. IR splicing, thereby recapitulating in human DM1 muscle cells the role played by CnA signaling in the complex mechanisms causing DM1 pathogenicity.
In contrast to these observations, however, RyR1 and CAPZB alternative splicing profiles were not affected by CnA inhibition, hence showing some level of specificity. In this context, both RyR1 and CAPZB alternative splicing patterns have previously been shown to be CUGBP1-dependent (27, 56, 69) . While in our work here CUGBP1 levels are increased by CsA-treatment, RyR1 and CAPZB splicing is not affected in CsA-treated muscles. This may be surprising at first but suggests that under these conditions, the CsA-dependent CUGBP1 increase was not sufficient to promote alternative splicing changes of these pre-mRNAs, and/ or that other RBP may be involved.
In DM1, the increase in CUGBP1 is known to be mediated by its hyperphosphorylation and stabilization by PKCa and bII (70), as well as via glycogen synthase kinase 3b (GSK3b) and cyclin D3-CDK4 (53) . Accordingly, pharmacological inhibition of PKC or GSK3b in the inducible heart-specific DM1 mouse model (EpA960) or in HSA-LR mice, respectively, ameliorates the DM1 phenotype (53, 71) . Recent genetic deletion of PKCa and bII in DM1 mice indicate that other PKC isoforms or kinases also contribute to this increase in CUGBP1 (72) . However, the mechanism by which PKC is activated in DM1 remains unknown. Interestingly, conventional PKC isoforms (PKC a, b and c) require calcium for their activation while other isoforms (PKC d, e, h and g) do not (73) . This suggests that the increase in [Ca 2þ ] i observed in DM1 muscle participates in the activation of the PKC pathway and CUGBP1 increase. One of the questions raised by our findings concerns the impact of CnA inhibition on CUGBP1 levels. CnA is a protein phosphatase that interacts with and controls the phosphorylation state of multiple proteins, the most studied being NFAT (74) . One possibility therefore is that CnA may act to dephosphorylate CUGBP1, thereby contributing to the regulation of its phosphorylation status and, hence, its stability. In DM1, the combined action of PKC, GSK3b and cyclin D3-CDK4 signaling may counterbalance the action of hyperactivated CnA. Nonetheless, following pharmacological inhibition of CnA in DM1 mice, we observed an increase in CUGBP1 levels which is coherent with the notion that the CnA phosphatase activity may indeed act directly on CUGBP1 phosphorylation state.
The findings of our study show that calcium-CnA signaling is hyperactivated in DM1. This raises the question on the importance of this signaling pathway in the etiology of DM1 and its relevance as a potential therapeutic avenue for the disease. In this context, crucial information can be learned from other muscular dystrophies. In Duchenne muscular dystrophy (DMD), absence of the structural protein dystrophin at the sarcolemma leads to increased fiber damage. In particular, dystrophindeficiency in skeletal muscle fiber results in increased membrane fragility and leakiness, resulting in perturbations in calcium homeostasis (75) . For several years, our laboratory has been interested in examining the therapeutic potential of CnA signaling for DMD. Collectively, work from our laboratory and others showed that activation of CnA is highly beneficial to mdx mice, a mouse model of DMD. Indeed, expression of a constitutively active form of CnA ameliorates the dystrophic phenotype (76, 77) whereas its inactivation with pharmacological inhibitors or small peptides (CaMBP) exacerbate the pathology (78, 79) . Furthermore, overexpression of NFAT-transcriptional activator FHL1 in mdx mice has also been shown to improve the symptoms (36) . Along those lines, and as we have observed in the present work, decreases in the expression of SERCA1 and increases in SLN levels have also been reported in mdx mice (80) . Thus, other therapeutic strategies for DMD have targeted SERCA1 and overexpression strategies in mdx mice resulted in improvements of the dystrophic phenotype (81, 82) . Therefore, our current observations showing that hyperactivation of CnA signaling in DM1 muscle cells represents a beneficial compensatory event to DM1, suggests that further activation of this pathway would ameliorate DM1 symptoms in muscle as seen previously in DMD muscle (76, 77) . Cell culture, lentivirus production, infections and treatments Human DM1 fibroblasts (GM03132, Coriell Cell Repositories) were maintained in growth medium (DMEM 10% fetal bovine serum [HyClone, Thermo Fisher Scientific], 100 U/ml penicillin, 100 lg/ml streptomycin) (4). Lentiviral particles were produced as previously described (6) , and the conditioned medium containing lentiviral particles used to infect DM1 cells in the presence of 6 lg/ml of Polybrene (Sigma-Aldrich). Infected cells were grown for at least 3 days before being considered myoblasts. DM1 myoblasts were treated with CsA (Sigma-Aldrich).
Materials and Methods

Antibodies
Animal models and treatments
All procedures were approved by the University of Ottawa Animal Care Committee and were in compliance with the guidelines of the Canadian Council on Animal Care and the Animals for Research Act. Control FVB/N (Charles River, Sherbrooke, QC, Canada), control HSA-SR and DM1 HSA-LR line LR20b (31) were used in this study. DM1 mice were treated twice daily for 28 days with either CsA (Sandimmune, Novartis, Dorval, Canada; 25 mg/kg/day, subcutaneously) or saline (control) as previously described (41, 46) . Muscles were dissected and either: (i) frozen and crushed in liquid nitrogen for protein and RNA extraction or (ii) embedded in Tissue-Tek OCT compound (VWR, Mississauga, Canada) and frozen in isopentane cooled with liquid nitrogen for cryostat sectioning.
Immunofluorescence and fiber typing 
Histochemical staining
For H&E staining, cryostat cross-sections were stained with hematoxylin and eosin, dehydrated with successive 70, 95 and 100% ethanol washes, cleared with toluene and mounted with Permount (Fisher Scientific).
RNA fluorescence in situ hybridization
Cryostat cross-sections were covered with 40% formamide 2Â saline-sodium citrate (SSC) for 10 min and then incubated with 10 ng of Cy3-labelled (CAG)10 oligonucleotide probe diluted in hybridization buffer (40% formamide, 2Â SSC, 0.2% BSA, 10% dextran sulfate, 2mM vanadyl adenosine complex, 1 mg/ml tRNA and salmon sperm DNA) for 2 h. Following washes, slides were mounted with Vectashield medium containing DAPI (Vector Labs/Cederlane).
Image acquisition
Images were visualized on a Zeiss Axio Imager.M2 upright microscope, equipped with Zeiss 63Â Plan-Apochromat 1. 
RNA extraction, reverse transcription and PCR
Total RNAs were extracted using TriPure (Roche/Sigma-Aldrich). 1 lg of RNAs were DNase-treated (Ambion/ThermoFisher Scientific), and cDNAs were produced with MuLV Reverse Transcriptase (Applied Biosystems/ThermoFisher Scientific). PCRs were performed using GoTaq (Promega/Fisher Scientific) according to manufacturer's instructions. The sequences of the primers were as follows: m-SERCA1, fwd, 5 0 -ATCTTCAAGCTCCGGGC CCT-3 0 , and rev, 5 0 -CAGCTTTGGCTGAAGATGCA-3 0 ; m-RyR1, fwd, 
Statistical analysis
Student's t-tests were used to determine whether differences between groups were significant. The level of significance was set at P 0.05. *P 0.05, **P 0.01 and ***P 0.001. Means plus/minus SEM are presented throughout, unless otherwise specified.
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